Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer

Mesinovic, Denis LU ; Bobjer, Johannes LU ; Hagberg, Oskar LU ; Aljabery, Firas ; Gårdmark, Truls ; Jahnson, Staffan ; Jerlström, Tomas ; Kjölhede, Henrik LU ; Malmström, Per Uno and Ströck, Viveka , et al. (2026) In Scandinavian Journal of Urology 61. p.127-130
Abstract

The International Bladder Cancer Group (IBCG) has proposed a prognostic model for intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) for clinical decision-making. We applied the IBCG IR model in a population-based Swedish setting in patients with primary IR NMIBC diagnosed 2013-2014 in BladderBaSe 2.0. Patients were stratified into low-risk (unifocal and tumour size < 3 cm) and intermediate-risk (multiple and/or tumour size ≥ 3 cm) for estimation of 1- and 3-year recurrence-free survival (RFS). Among 710 patients with IR NMIBC, 329 (46%) and 381 (54%) were categorized as low- and intermediate-risk, respectively. Probabilities of disease recurrence or death at 1 and 3 years in low-risk patients were 19% (95% confidence... (More)

The International Bladder Cancer Group (IBCG) has proposed a prognostic model for intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) for clinical decision-making. We applied the IBCG IR model in a population-based Swedish setting in patients with primary IR NMIBC diagnosed 2013-2014 in BladderBaSe 2.0. Patients were stratified into low-risk (unifocal and tumour size < 3 cm) and intermediate-risk (multiple and/or tumour size ≥ 3 cm) for estimation of 1- and 3-year recurrence-free survival (RFS). Among 710 patients with IR NMIBC, 329 (46%) and 381 (54%) were categorized as low- and intermediate-risk, respectively. Probabilities of disease recurrence or death at 1 and 3 years in low-risk patients were 19% (95% confidence interval [CI]: 15-23) and 41% (95% CI: 35-46), versus 27% (95% CI: 22-31) and 45% (95% CI: 40-50) in the intermediate-risk group. In a sensitivity analysis including only patients receiving serial adjuvant instillations (n = 152) the corresponding probabilities at 1 and 3 years were 19% (95% CI: 10-28) and 33% (95% CI: 22-43) versus 15% (95% CI: 7-23) and 31% (95% CI: 20-41), respectively. Thus, no clinically meaningful difference in recurrence-free survival was observed between International Bladder Cancer Group low- and intermediate-risk groups in this population-based primary non-muscle invasive bladder cancer setting.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Urology
volume
61
pages
4 pages
publisher
Taylor & Francis
external identifiers
  • pmid:41995252
  • scopus:105035817272
ISSN
2168-1813
DOI
10.2340/sju.v61.45712
language
English
LU publication?
yes
id
422b5cf4-d2d2-451c-bcaf-12d1b4b30ff7
date added to LUP
2026-05-25 12:21:14
date last changed
2026-05-25 12:22:31
@article{422b5cf4-d2d2-451c-bcaf-12d1b4b30ff7,
  abstract     = {{<p>The International Bladder Cancer Group (IBCG) has proposed a prognostic model for intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) for clinical decision-making. We applied the IBCG IR model in a population-based Swedish setting in patients with primary IR NMIBC diagnosed 2013-2014 in BladderBaSe 2.0. Patients were stratified into low-risk (unifocal and tumour size &lt; 3 cm) and intermediate-risk (multiple and/or tumour size ≥ 3 cm) for estimation of 1- and 3-year recurrence-free survival (RFS). Among 710 patients with IR NMIBC, 329 (46%) and 381 (54%) were categorized as low- and intermediate-risk, respectively. Probabilities of disease recurrence or death at 1 and 3 years in low-risk patients were 19% (95% confidence interval [CI]: 15-23) and 41% (95% CI: 35-46), versus 27% (95% CI: 22-31) and 45% (95% CI: 40-50) in the intermediate-risk group. In a sensitivity analysis including only patients receiving serial adjuvant instillations (n = 152) the corresponding probabilities at 1 and 3 years were 19% (95% CI: 10-28) and 33% (95% CI: 22-43) versus 15% (95% CI: 7-23) and 31% (95% CI: 20-41), respectively. Thus, no clinically meaningful difference in recurrence-free survival was observed between International Bladder Cancer Group low- and intermediate-risk groups in this population-based primary non-muscle invasive bladder cancer setting.</p>}},
  author       = {{Mesinovic, Denis and Bobjer, Johannes and Hagberg, Oskar and Aljabery, Firas and Gårdmark, Truls and Jahnson, Staffan and Jerlström, Tomas and Kjölhede, Henrik and Malmström, Per Uno and Ströck, Viveka and Söderkvist, Karin and Ullén, Anders and Holmberg, Lars and Häggström, Christel and Liedberg, Fredrik}},
  issn         = {{2168-1813}},
  language     = {{eng}},
  pages        = {{127--130}},
  publisher    = {{Taylor & Francis}},
  series       = {{Scandinavian Journal of Urology}},
  title        = {{Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer}},
  url          = {{http://dx.doi.org/10.2340/sju.v61.45712}},
  doi          = {{10.2340/sju.v61.45712}},
  volume       = {{61}},
  year         = {{2026}},
}